logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Visceral leishmaniasis and HIV coinfection in East Africa

Diro EGJ, Lynen L, Ritmeijer KKD, Boelaert M, Hailu ADE,  et al.
2014-06-26 • PLOS Neglected Tropical Diseases
2014-06-26 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload a...
Journal Article
|
Commentary

Visceral Leishmaniasis Relapse in HIV Patients-A Role for Myeloid-Derived Suppressor Cells?

Van der Bergh R, Van Ginderachter J, Schouppe E, Desimmie B, Hailu ADE,  et al.
2014-09-11 • PLOS Neglected Tropical Diseases
2014-09-11 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R,  et al.
2016-09-14 • PLOS Neglected Tropical Diseases
2016-09-14 • PLOS Neglected Tropical Diseases
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBis...
Journal Article
|
Research

Development of a cross-over randomized trial method to determine the acceptability and safety of novel ready-to-use therapeutic foods

Dibari F, Bahwere P, Huerga H, Hailu ADE, Owino V,  et al.
2013-01-01 • BMC Nutrition
2013-01-01 • BMC Nutrition
To develop a method for determining the acceptability and safety of ready-to-use therapeutic foods (RUTF) before clinical trialing. Acceptability was defined using a combination of three...
Protocol
|
Research Protocol

A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hailu ADE, Diro EGJ, Kolja S, Ritmeijer KKD, Yifru S,  et al.
2018-07-01
2018-07-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
Journal Article
|
Research

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S,  et al.
2010-10-26 • PLOS Neglected Tropical Diseases
2010-10-26 • PLOS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is in...
Protocol
|
Research Protocol

Research Protocol - A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hailu ADE
2014-10-01
2014-10-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|
Research

Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial

Diro EGJ, Ritmeijer KKD, Boelaert M, Alves F, Mohammed R,  et al.
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Journal Article
|
Research

Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme

Kimutai R, Musa AM, Njoroge SM, Omollo R, Alves F,  et al.
2017-03-01 • Clinical Drug Investigation
2017-03-01 • Clinical Drug Investigation
INTRODUCTION
In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscu...
Journal Article
|
Research

A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?

van Griensven J, Diro EGJ, Lopez-Velez R, Ritmeijer KKD, Boelaert M,  et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
In the wake of the HIV epidemic, visceral leishmaniasis (VL), a disseminated protozoan infection caused by the Leishmania donovani complex, has been re-emerging, particularly in North Et...